The role of Sin3B in coordinating cell cycle exit and differentiation in hematopoiesis
Sin3B 在协调造血细胞周期退出和分化中的作用
基本信息
- 批准号:10005263
- 负责人:
- 金额:$ 4.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-11 至 2022-01-10
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Myelocytic LeukemiaAdultBlood CellsBone MarrowCell CompartmentationCell CycleCell Cycle ProgressionCell Cycle RegulationCell physiologyCellsChromatinChromatin Remodeling FactorClone CellsComplexDNA biosynthesisDefectEngraftmentGene ExpressionGenesGenetic TranscriptionGenomicsHematologic NeoplasmsHematopoiesisHematopoieticHematopoietic NeoplasmsHematopoietic SystemHematopoietic stem cellsHemorrhageHistone DeacetylaseHome environmentHomeostasisImpairmentIndividualLabelLeadMaintenanceMalignant - descriptorMalignant NeoplasmsMediatingModelingMusMyelosuppressionNaturePancytopeniaPathway AnalysisPhenotypePlayPopulationProductionProliferatingPropertyProteinsRecording of previous eventsRefractoryRegenerative responseRegulationRelapseRepressionResistanceRoleScaffolding ProteinSepsisStressSystemTechniquesTestingTransgenesTranslatingTransplantationbasecell typechemotherapyconditional knockoutdifferential expressionexhaustionexperimental studygenomic locushematopoietic differentiationhematopoietic stem cell differentiationhematopoietic stem cell quiescencehematopoietic stem cell self-renewalleukemia treatmentleukemic stem cellnew therapeutic targetnovelnovel therapeuticsprogramsrecruitrelapse patientsresponseself-renewalstem cell biologystem cellsstemnesssuccesstranscription factortranscriptome sequencing
项目摘要
PROJECT SUMMARY
Hematopoietic stem cells (HSCs) in the bone marrow must maintain a constant production of effector blood
cells to maintain homeostasis. Key to this is the ability for HSCs, at a population level, to self-renew and maintain
quiescence. Central to the maintenance of quiescence and to a functional stem cell pool is regulation of cell
cycle entry and exit. Many repressive chromatin-modifying complexes exist that target genes related to
proliferation and DNA replication. Perturbations in the maintenance of quiescence or differentiation can lead to
bone marrow failure or malignant transformation. We have recently demonstrated that the chromatin scaffolding
protein Sin3B is essential for the maintenance of functional HSCs in mice. Sin3B recruits histone deacetylases
and through interaction with sequence specific transcription factors modulates local chromatin at discrete
genomic loci and represses transcription. Loss of Sin3B diminishes HSCs ability to maintain quiescence and
properly differentiate in a competitive transplantation setting. This proposal seeks to understand the Sin3B-
dependent transcriptional network necessary for maintenance of HSC function. Additionally, we seek to translate
these studies to Acute Myeloid Leukemia, a malignancy characterized by rapid proliferation of blasts that are
blocked in differentiation. Specifically, it is thought that patients relapse due to the presence of chemotherapy-
resistant Leukemic Stem Cells (LSCs). These LSCs have many similarities to HSCs including quiescence and
self-renewal properties, which is hypothesized to be responsible for their resistance to conventional
chemotherapy. We propose to understand the role Sin3B plays in maintaining AML LSCs and to determine if
targeting of Sin3B presents a novel therapeutic strategy to sensitize LSCs to treatment. This proposal aims to
couple acute deletion of Sin3B with chemotherapy treatment to assess if relapse in AML can be abrogated
through selective targeting of LSCs.
项目概要
骨髓中的造血干细胞 (HSC) 必须维持效应血液的持续产生
细胞维持稳态。其关键在于 HSC 在群体水平上自我更新和维持的能力
静止。维持静止和功能性干细胞库的核心是细胞的调节
循环进入和退出。存在许多抑制性染色质修饰复合物,其目标基因与
增殖和DNA复制。维持静止或分化的扰动可能导致
骨髓衰竭或恶变。我们最近证明了染色质支架
Sin3B 蛋白对于小鼠 HSC 功能的维持至关重要。 Sin3B 招募组蛋白脱乙酰酶
并通过与序列特异性转录因子的相互作用,以离散的方式调节局部染色质
基因组位点并抑制转录。 Sin3B 的缺失会降低 HSC 维持静止和
在竞争性移植环境中正确区分。该提案旨在了解 Sin3B-
维持 HSC 功能所必需的依赖转录网络。此外,我们寻求翻译
这些研究针对急性髓系白血病,这是一种以原始细胞快速增殖为特征的恶性肿瘤,
分化受阻。具体来说,人们认为患者复发是由于化疗的存在——
耐药性白血病干细胞(LSC)。这些 LSC 与 HSC 有许多相似之处,包括静止和
自我更新的特性,被认为是它们对传统的抵抗力的原因
化疗。我们建议了解 Sin3B 在维持 AML LSC 中所扮演的角色,并确定是否
Sin3B 的靶向提供了一种使 LSC 对治疗敏感的新治疗策略。该提案旨在
将 Sin3B 急性缺失与化疗结合起来,以评估是否可以消除 AML 的复发
通过选择性靶向LSC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Calderon其他文献
Alexander Calderon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Calderon', 18)}}的其他基金
Sin3B’s role in coordinating cell cycle exit and differentiation in hematopoiesis - Funded Extension
Sin3B 在协调造血细胞周期退出和分化中的作用 - 资助扩展
- 批准号:
10399347 - 财政年份:2018
- 资助金额:
$ 4.55万 - 项目类别:
The role of Sin3B in coordinating cell cycle exit and differentiation in hematopoiesis
Sin3B 在协调造血细胞周期退出和分化中的作用
- 批准号:
9611826 - 财政年份:2018
- 资助金额:
$ 4.55万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 4.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 4.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 4.55万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 4.55万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 4.55万 - 项目类别:














{{item.name}}会员




